Search

Displaying results 2491 - 2500 of 2507 in total
  1. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in the majority of infant acute lymph...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    Taletrectinib is an orally available small molecule kinase inhibitor. It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. Gene...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  3. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-produc...

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. By b...

    Categories: Cytochrome P-450 CYP3A Inhibitors, P-glycoprotein substrates
  6. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that ar...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Hydrastinine

    go.drugbank.com/drugs/DB19359
    Experimental

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Fluroxene

    go.drugbank.com/drugs/DB20681
    Experimental

    Fluroxene is a small molecule drug. Fluroxene has a monoisotopic molecular weight of 126.03 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Drug

    Telmapitant

    go.drugbank.com/drugs/DB20768
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Telmapitant is a neurokinin NK1​ (substance P) receptor antagonist. Telmapitant has a monoisotopic molecular weight of 515.16 Da.

  10. Drug

    Taltobulin

    go.drugbank.com/drugs/DB20832
    Experimental

    Taltobulin is a small molecule drug. Taltobulin has a monoisotopic molecular weight of 473.33 Da.

    Categories: P-glycoprotein substrates